Free Trial
CVE:APM

Andean Precious Metals 8/13/2024 Earnings Report

Andean Precious Metals logo
C$1.29 +0.09 (+7.50%)
As of 01/8/2025

Andean Precious Metals EPS Results

Actual EPS
C$0.08
Consensus EPS
C$0.08
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Andean Precious Metals Revenue Results

Actual Revenue
$95.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Andean Precious Metals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Andean Precious Metals Earnings Headlines

Our $1 AI stock to buy right now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.
Stocks in play: Andean Precious Metals Corp.
See More Andean Precious Metals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Andean Precious Metals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Andean Precious Metals and other key companies, straight to your email.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

View Andean Precious Metals Profile

More Earnings Resources from MarketBeat